United StatesResearchers have developed an experimental therapy for glioblastoma, one of the deadliest forms of brain cancer, by targeting a protein called GPNMB that appears on both cancer cells and supporting immune cells. The treatment, described in a study published in *Nature*, uses CAR-T cells engineered to attack GPNMB, potentially disrupting the tumor's ability to thrive. While still in preclinical testing, the approach represents a shift from traditional methods that focus solely on cancer or immune cells. Scientists argue that glioblastomas function as an 'ecosystem' involving both malignant and non-malignant cells, suggesting that future therapies must consider this complex interaction. The research highlights a growing belief that effective treatments may require addressing the entire tumor environment rather than individual components.
Procjena pristranosti (Sredina): The article presents scientific research without overt ideological framing. It focuses on medical discovery and clinical implications, avoiding political commentary or advocacy. The tone is objective, emphasizing the novelty of the treatment and its potential impact on patient outcomes without align
Zašto ove ocjene (Činjenice 95 · Objektivnost 85): Factuality is high as the article accurately reports on a recent study published in Nature, providing details about the research methodology and findings. The article cites a direct quote from a researcher, adding credibility. Objectivity is slightly lower due to some emotionally charged language su
